Gossamer Bio Inc. (NASDAQ: GOSS) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 3 articles on GOSS since May 18, 2026, most recently "Gossamer Bio (GOSS) Secures Up to $250M Private Placement Tied to Seralutinib FDA Milestones" on Friday, August 21, 2026. Coverage to date spans Health Care, tracking GOSS's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
Price
$0.14
Today
-10.46%
Mkt Cap
$78M
52W High
$3.87
52W Low
$0.11
Data via Finnhub · refreshes hourly · not financial advice
Gossamer Bio structured a $250M private placement with $25M upfront and $125M contingent on FDA acceptance of its seralutinib NDA for pulmonary arterial hypertension.
Gossamer Bio swapped $181M of 2027 convertible notes into new secured debt and equity, leaving $18.95M of old notes outstanding and issuing 317.6M shares.
Biotech firm launches debt exchange offer to eliminate over $120 million in liabilities as part of restructuring plan.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.